Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - Haematological malignancies

886MO - Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

Date

18 Sep 2020

Session

Mini Oral - Haematological malignancies

Topics

Immunotherapy

Tumour Site

Lymphomas

Presenters

Pier Luigi Zinzani

Citation

Annals of Oncology (2020) 31 (suppl_4): S590-S598. 10.1016/annonc/annonc261

Authors

P.L. Zinzani1, R. Ramchandren2, A. Santoro3, E. Paszkiewicz-Kozik4, R. Gasiorowski5, N.A. Johnson6, J.S..R. de Oliveira7, V. Buccheri8, G.F. Perini9, M. Dickinson10, A. McDonald11, M. Ozcan12, N. Sekiguchi13, M. Raut14, Y. Zhu14, A. Nahar14, P. Marinello14, J. Kuruvilla15

Author affiliations

  • 1 Experimental, Diagnostic And Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli” – University of Bologna, 40126 - Bologna/IT
  • 2 Medicine, University of Tennessee, 37996 - Knoxville/US
  • 3 Oncology, Humanitas Cancer Center, 20089 - Milan/IT
  • 4 Medical Oncology, Maria Sklodowska-Curie National Institute of Oncology, 00-001 - Warsaw/PL
  • 5 Hematology, Concord Hospital, University of Sydney, NSW 2139 - Sydney/AU
  • 6 Hematology, Jewish General Hospital, H3T 1E2 - Montreal/CA
  • 7 Medical Oncology, Casa de Saude Santa Marcelina, 08115-100 - Sao Paulo/BR
  • 8 Clinical Medicine, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, 01246-903 - Sao Paulo/BR
  • 9 Hematology, Hospital Israelita Albert Einstein, 05651-900 - Sao Paulo/BR
  • 10 Lymphoma Disease, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, 3000 - Melbourne/AU
  • 11 Hematology, Pretoria East Hospital, 0181 - Pretoria/ZA
  • 12 Internal Medicine, Ankara Üniversitesi Tip Fakültesi, 06230 - Ankara/TR
  • 13 Medical Oncology, National Hospital Organization Disaster Medical Center, 190-0014 - Tokyo/JP
  • 14 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 15 Medical Oncology And Hematology, Princess Margaret Cancer Centre, ON M5G 2C1 - Toronto/CA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 886MO

Background

In the phase III KEYNOTE-204 (NCT02684292) study, pembro demonstrated clinically meaningful improvement in PFS vs BV in patients (pts) with R/R cHL. HRQoL was evaluated.

Methods

Pts aged ≥18 y, were post−autologous stem cell transplant (auto-SCT) or ineligible for auto-SCT, measurable disease and ECOG PS 0 or 1 were randomized 1:1 to pembro 200 mg IV Q3W or BV 1.8 mg/kg IV Q3W. EORTC QLQ-C30 and EuroQoL EQ5D scales were protocol-specified exploratory end points administered electronically at baseline (BL) and Q6W up to wk 24 and Q12W thereafter. Analysis population included pts who received ≥1 dose of study treatment and completed ≥1 HRQoL assessment. Least-squares mean (LSM) changes from BL to prespecified wk 24 end point were calculated. Time to deterioration (TTD; ≥10-point decline from BL) was assessed by Kaplan-Meier. Differences evaluated using two sided p-values not controlled for multiplicity.

Results

296 pts were included (pembro, 146; BV, 150). Completion and compliance rates were >90% for both groups at BL and remained high (>80%) at wk 24. Improvement was observed at wk 24 with pembro in the QLQ-C30 global health status/quality of life (GHS/QoL; LSM difference [95% CI]: 8.60 [3.89-13.31]; P=0.0004) and physical functioning (6.42 [1.87-10.62]; P=0.0054) scores vs BV, which showed a worsening. Similar improvements were seen for pembro in EQ5D utility (0.09 [0.04-0.14); P=0.0004) and VAS scores (6.12 [1.91-10.34]; P=0.0046). Pembro demonstrated an improvement in QLQ-C30 GHS/QoL score vs BV in pts who progressed (11.76 [5.66-17.86]; P=0.0002) and did not progress (5.10 [–2.53, 12.73]; P=0.187). Prolonged TTD was observed with pembro vs BV for QLQ-C30 GHS/QoL (HR, 0.40; 95% CI, 0.22-0.74; P=0.003) and physical functioning score (HR, 0.56; 95% CI, 0.32-0.97; P=0.034).

Conclusions

Among R/R cHL pts, pembro demonstrated improvement in HRQoL compared with BV, which showed a worsening. These data, along with statistically significant and clinically meaningful improvements in PFS, support pembro as new standard of care for pts who relapsed post auto-SCT or are ineligible for auto-SCT.

Clinical trial identification

NCT02684292.

Editorial acknowledgement

Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Legal entity responsible for the study

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Funding

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

P.L. Zinzani: Advisory/Consultancy, Speaker Bureau/Expert testimony: Verastem; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celltrion; Advisory/Consultancy, Speaker Bureau/Expert testimony: Gilead; Advisory/Consultancy, Speaker Bureau/Expert testimony: Janssen-Cilag; Advisory/Consultancy, Speaker Bureau/Expert testimony: BMS; Advisory/Consultancy, Speaker Bureau/Expert testimony: Servier; Advisory/Consultancy: Sandoz; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Immune Design; Advisory/Consultancy, Speaker Bureau/Expert testimony: Celgene; Advisory/Consultancy, Speaker Bureau/Expert testimony: Portola; Advisory/Consultancy, Speaker Bureau/Expert testimony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eusa Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: Kyowa Kirin; Advisory/Consultancy: Sanofi. R. Ramchandren: Advisory/Consultancy: Seattle Genetics, Sandoz-Novartis, Pharmacyclics/Janssen, Bristol-Myers Squibb; Research grant/Funding (self): Research Grant/Funding Merck, Seattle Genetics, Janssen, Genentech You. A. Santoro: Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony: Servier; Advisory/Consultancy, Speaker Bureau/Expert testimony: Gilead Sciences; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/Consultancy, Speaker Bureau/Expert testimony: Eisai; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bayer; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Sanofi; Advisory/Consultancy, Speaker Bureau/Expert testimony: ArQule; Speaker Bureau/Expert testimony: Takeda; Speaker Bureau/Expert testimony: Roche; Speaker Bureau/Expert testimony: AbbVie; Speaker Bureau/Expert testimony: Amgen; Speaker Bureau/Expert testimony: Celgene; Speaker Bureau/Expert testimony: AstraZeneca; Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Sandoz; Speaker Bureau/Expert testimony: Novartis. E. Paszkiewicz-Kozik: Travel/Accommodation/Expenses: Roche; Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Expenses: Celgene. R. Gasiorowski: Honoraria (self): MSD; Honoraria (self): Takeda; Honoraria (self): Novartis; Honoraria (self): AbbVie. N.A. Johnson: Honoraria (self), Advisory/Consultancy: Roche/Genentech; Honoraria (self), Advisory/Consultancy: Merck; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy, Research grant/Funding (self): AbbVie. V. Buccheri: Advisory/Consultancy, Advisory board: AstraZeneca; Research grant/Funding (institution): MSD; Research grant/Funding (institution): Roche; Research grant/Funding (institution): Seattle Genetics; Research grant/Funding (institution), Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Expenses: AbbVie. G.F. Perini: Honoraria (self), Speaker Bureau/Expert testimony: Janssen; Honoraria (self): Takeda; Honoraria (self): AbbVie. M. Dickinson: Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): MSD; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Roche; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Takeda; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Celgene; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/Funding (institution): Novartis. M. Ozcan: Research grant/Funding (institution): MSD; Research grant/Funding (institution): Bayer; Research grant/Funding (institution): Celgene; Honoraria (self), Research grant/Funding (institution): Roche; Research grant/Funding (institution): Janssen; Honoraria (self), Research grant/Funding (institution): Takeda; Research grant/Funding (institution): Archigen; Research grant/Funding (institution): Novartis; Honoraria (self), Research grant/Funding (institution): AbbVie; Honoraria (self): Amgen; Honoraria (self): BMS. N. Sekiguchi: Research grant/Funding (institution): Ono; Research grant/Funding (institution): A2 Healthcare; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Astellas; Research grant/Funding (institution): Daiichi Sankyo; Research grant/Funding (institution): Janssen; Research grant/Funding (institution): Merck Sharp & Dohme; Research grant/Funding (institution): Otsuka; Research grant/Funding (institution): Pfizer; Research grant/Funding (institution): PPD-SNBL,; Research grant/Funding (institution): Sumitomo Dainippon. M. Raut, Y. Zhu, A. Nahar: Full/Part-time employment: Merck & Co., Inc. P. Marinello: Travel/Accommodation/Expenses, Shareholder/Stockholder/Stock options, Full/Part-time employment: Merck & Co., Inc. J. Kuruvilla: Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy: Bristol-Myers Squibb; Honoraria (self): Amgen; Honoraria (self): Celgene; Honoraria (self): AstraZeneca; Honoraria (self), Advisory/Consultancy: Gilead Sciences; Honoraria (self), Research grant/Funding (self): Janssen; Honoraria (self), Advisory/Consultancy: Karyopharm Therapeutics; Honoraria (self), Advisory/Consultancy: Merck; Honoraria (self): Novartis; Honoraria (self), Research grant/Funding (self): Roche; Honoraria (self), Advisory/Consultancy: Seattle Genetics; Advisory/Consultancy: Roche/Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.